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Table 1. Pearson correlation coefficients
NTX-I CTX-II HA COMP
Classic TQOL
K-L 0-IV 0.265* 0.298* 0.302** 0.226*
JSN 0-3 0.229 0.229 0.430*** 0.297**
TQOL-Lite
K-L 0-IV 0.282* 0.321* 0.362*** 0.263*
JSN 0-3 0.267* 0.200 0.398*** 0.276**
*p < 0.05 (2-tailed test). **p < 0.01 level (2-tailed test). *p < 0.001 level (2-tailed
test).
Sum Severity of scores for hips and knees provided similar
results to the original TQOL assessment tool, and simplifying its
general use. The full TQOL assessment tool should, however,
be considered to evaluate biomarker correlations for maximal
accuracy in overall assessments.
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Purpose: In humans, one of the most promising biochemical
markers of cartilage degradation is the C-terminal crosslinked
telopeptide of type II collagen (CTX-II). The rabbit model of an-
terior cruciate ligament transaction (ACLT) is a valuable animal
model of osteoarthritis (OA). The aim of this study was to de-
scribe the changes of cartilage degradation by measuring type II
collagen degradation fragments (CTX-II) in the urine of rabbits in
this ACTL model of OA.
Methods: 2 experimental groups of New Zeland rabbits were
studied: ACLT (n=32) and sham operated rabbits (n=32). A
medial parapatellar approach was used allowing the transection
of the ACL under complete visualisation in the middle third of the
ligament with the stumps left in the joint. Sham surgery consisted
of a complete arthrotomy including full visualisation of the ACL
which was always checked as fully intact. This procedure was
performed on only the right knee. At 2, 4, 8 and 12 weeks after
surgery, 8 rabbits per experimental group were sacrificed.
A macroscopic grading was performed on the right and left knee
joints using the scheme of the International Cartilage Repair
Society. Specific areas and sums of areas of all joint sites were
analysed. For microscopic evaluation, 4 muem sections of the
central tibial plateaus were stained with H&E and Safranin O.
Histologic analysis was performed with a dedicated grading sys-
tem accounting for pathologic alterations of proteoglycan content,
matrix structure, cellularity, tidemark duplication, and osteophyte
formation, basically a modified Mankin scheme.
Urinary CTX-II was measured by ELISA in 24 hr urine samples,
which were obtained during the 24 hrs before surgery and again
during 24 hrs each sacrifice time points. Intra- and inter - assay
CV was below 10%. Data were corrected for creatinine excretion
measured by standard colorimetric assay.
Results: All animals (n = 64) were free of signs of infection
and had a normal postoperative course. Lesions advanced with
time following the ACLT: at 2 weeks after ACLT, macroscopically
visible lesions were only detected at the medial femoral site (p<
0.05). With time, lesion size increased and lesions appeared at
more joint sites. At 12 weeks after ACLT, medial and lateral tibiae
as well as both femoral condyles showed statistically significant
lesions. Histologic scores showed early OA after ACLT, when
compared with the unoperated contralateral side. Also, a statis-
tically significant difference was seen versus the sham surgery
group at the respective timepoints. In sham operated animals,
compared to pre-operated controls, urinary CTX-II did not signif-
icant changed during the first 8 weeks and then decreased by
65% (p=0.01) at12 weeks. In ACTL rabbits, there was a median
77% increased in CTX-II levels for weeks after surgery and then
values decreased.
Conclusions: In this ACLT-rabbit model, urinary CTX-II levels
peaked 4 weeks after surgery suggesting that it may be valuable
to monitor cartilage degradation in this model of OA.
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Purpose: The CTX II assay has been used to examine the type
II collagen telopeptide concentration in human synovial fluid,
explant media, and urine of rats and humans. These reports
demonstrate that CTX II may be one of the most beneficial
biomarkers for diagnosing, predicting and monitoring changes
that occur to the articular cartilage in osteoarthritis (OA) patients.
Based on these reports, it seems logical that the CTX II assay has
the potential to help diagnose, predict and monitor OA changes
in horses since the horse is a good translational model of OA for
biomarker evaluation. Type II collagen is well conserved across
species, and Nordic Bioscience Diagnostics has demonstrated
that the amino acid sequence of the CartiLaps® epitope is 100%
conserved across many species including the horse. Thus, the
CartiLaps® assay has the potential to be used successfully in
equine models of OA.
Methods: Serum Pre-Clinical Cartilaps® ELISAs (Nordic Bio-
science Diagnostics) were used for this validation study ac-
cording to manufacturer protocols. Internal quality control (QC)
samples were prepared using the highest concentration stan-
dard provided by the manufacturer (259.4 pg/ml). To create QC
samples, fresh synovial fluid (SF) was collected aseptically from
6 middle carpal and 6 radiocarpal joints from 3 normal horses.
The samples were pooled together for further processing and
analysis. Pooled samples were spiked with a known amount of
standard to create samples with high, medium and low levels
of CTX II. The QC samples were used to determine the pre-
cision, specificity, sensitivity, accuracy, linearity of dilution, and
stability of this assay with equine SF. To ensure that the as-
say could detect different biological activity, previously stored SF
samples were analyzed from normal rested (n=2) and treadmill
exercised horses (n=2), as well as those with naturally-occurring
osteochondral (OC) injuries (n=2).
Results: Reproducibility of the standard curve was evaluated
(n=6 plates) by computing mean optical density (OD) and percent
coefficient of variation (% CV) at each standard concentration.
The overall mean inter-assay CV of the standard OD values was
11.1% (range; 6.8-13.7%). Samples exhibited acceptable intra-
assay and inter-assay precision over 3 plates with an overall
mean CV of 5.2% (range; 0.3-18.8%) and 9.3% (range; 5.3-
13.2%), respectively. Parallelism of SF sample dilutions (1:2,
1:4, 1:8, and 1:10) was demonstrated when compared to the
standard curve (Figure 1).
Lowest detection limit of the assay was determined to be 6.6
pg/ml. Percent recovery was 64.2% for high, 79.4% for medium,
and 93.2% for low QC samples. Linearity of equine SF sample
dilutions (1:2, 1:4, 1:8, and 1:16), was demonstrated (Figure
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Fig. 1. Specificity was examined by mixing together the high, medium and low
quality control samples (mQC). This mixture was serially diluted at the following
dilutions: 1:2, 1:4, 1:8, and 1:10. The results of this serial dilution were then
compared to the standard curve that was derived using the standards provided
by the manufacturer by comparing the absorbance to the concentration. The
samples demonstrated parallelism to the master standard curve.
Fig. 2. Linearity of dilution was analyzed by serially diluting QC samples (high,
medium, and low) at the following dilutions: 1:2, 1:4, 1:8, and 1:10. The concen-
tration of each dilution was then determined from the standard curve and the
observed concentration was plotted against the reciprocal of the dilution (1/dilu-
tion).
2). There was no loss in the stability of the CTX II epitope
out to 4 freeze/thaw cycles. Differences in biological activity
were identified when examining SF samples from normal rested
horses (291 ± 58.5 pg/ml), horses treadmill exercised for 4
months (330.8 ± 124 pg/ml), and those with naturally-occurring
OC injuries (690.0 ± 69.3 pg/ml).
Conclusions: The Serum Pre-Clinical Cartilaps® ELISA is a
reproducible and valid assay for use with equine synovial fluid.
Acknowledgements: Study supported by Pfizer, Inc, Animal
Health Division.
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Purpose: To date, autologous chondrocyte transplantation (ACT)
is mainly used for the treatment of post-traumatic cartilage de-
generation or of osteochondrosis dissecans (OD). First studies
suggest that ACT might also be used for the treatment of os-
teoarthritis (OA). However, it is still unclear if the environment
in the osteoarthritic joint might hamper cartilage regeneration.
Therefore, we compared matrix metalloproteases (MMP) and cy-
tokine levels in synovial fluid from patients currently treated with
ACT with those of patients with generalized, primary OA or with
unilateral OA combined with axis-malalignment.
Methods: Knee synovial fluid (SF) was collected from OD-
patients (n=6, 33 ± 10 years), post-traumatic cartilage
degeneration-patients (n=9, 39 ± 12 years), unilateral OA-
patients (n=12, 53 ± 17 years), and primary OA-patients (n=19,
71 ± 9 years). Samples were collected before the cartilage
harvest for ACT, during diagnostical arthroscopy or before total
knee replacement, immediately frozen, and stored at -70°C until
measurement.
The concentration of cytokines and MMPs were determined
using a multiplex assay based on antibody-coated microspheres
(xMAP® Technology, Luminex, USA). IL-1β, IL-6, IL-8, IL-10,
IL-12 and TNFα were measured with the Beadlyte® Human
Multi-cytokine Detection System 2 (Upstate USA, Lake Placid,
NY); MMP-1, -2, -3, -7, -8, -9, -10, and -13 were measured
using a multiplexed bead-based assay system developed at our
institute.
Results: In SF of all four groups, high concentrations of MMP-
1, -3 and -9 (av. 119.7, 471.9, 1311.8 ng/ml respectively), and
medium levels of MMP-7 (av. 20.6 ng/ml) were present; MMP-10
(av. 0.4 ng/ml) was only present at very low levels, while MMP-
2, -8, and -13 could not be detected. No differences could be
detected between the different groups, except that MMP-levels
in SF from OD-patient appeared to be generally lower than
OA and traumatic cartilage degeneration. However, this only
reached significance for MMP-3 compared with post-traumatic
cartilage degeneration. IL-6 was the cytokine found in highest
concentration in the SF of most of the patients (av. 284.8 pg/ml).
In all groups IL-8 was present in medium levels (av. 39.6 pg/ml),
while IL-1β, IL-10, IL-12 and TNFα were present at baseline (av.
3.6-16.8 pg/ml). Again, no differences between the four groups
were found.
Conclusions: We conclude that although both inflammatory
cytokines and MMPs were present in the SF of all patients,
the levels of those did not differ between the OA, the post-
trauma and OD groups. Since patients of the last two groups are
routinely treated with the ACT with good results, the presence
of these cytokines and MMPs does not hamper the success of
this method. It might therefore be expected that the metabolic
environment in OA patients also would not prevent the usage of
ACT in these patients.
Acknowledgements: This work is supported by the BMBF (grant
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Purpose: Urine levels of C telopeptides of type I (CTX I) and II
(CTX II) collagens have been shown to be useful for the moni-
toring of patients with bone and articular diseases respectively.
The aim of the study was to assess differences of CTX I and
CTX II urine concentrations according to the musculoskeletal
diseases, and to investigate whether the levels of the biomarkers
can help for diagnosis.
